20/20 Biolabs Common Stock Total Revenue

20/20 Biolabs Common Stock's total revenue stands at $2M as of June 2026. That is below the sector sector average of $1.3B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

20/20 Biolabs Common Stock sits lower the its sector benchmark ($1.3B) with a total revenue of $2M. That is roughly 99.8% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Open the history chart to see whether 20/20 Biolabs Common Stock's total revenue is expanding or contracting. Sustained growth in total revenue can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how 20/20 Biolabs Common Stock's total revenue evolved across reporting periods, while the comparison chart places AIDX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.